

13:00-14:30	Poster Session II & Lunch (Foyer and Seminar Rooms First Floor)
14:30-16:30	Session 7 – Target discovery in cancer Session Chairs: Hubert Serve, Karen Vousden
14:30-14:40	Svenja Wiechmann, Goethe University Frankfurt, DE: Targeting Ras interactions: engineered Ras-binding domains as potent competitive inhibitors of oncogenic Ras
14:45-14:55	Manuel Kaulich, Goethe University Frankfurt, DE: High-fidelity multiplexed CRISPR/Cas libraries for functional interrogations
15:00-15:25	Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, US: Identification of new cancer vulnerabilities with functional genomic screens
15:30-15:55	Ivan Dikic, Goethe University Frankfurt, DE: Ubiquitin networks in cancer pathogenesis
16:00-16:25	Joseph Schlessinger, Yale University School of Medicine, New Haven, US: The role of endocrine FGFs in metabolism and cancer
16:30-17:00	Coffee Break (Foyer)
17:00-19:00	Session 8 – Targeting the untargetable: Myc and epigenetic reader domains Session Chairs: Michael Karin, Lisa Sevenich
17:00-17:25	Martin Eilers, University Würzburg, DE: MYCN in neuroblastoma: coordinating transcription and DNA replication
17:30-17:55	Laura Soucek, Vall d'Hebron Institute of Oncology, Barcelona, ES: Inhibiting Myc with Omomyc-derived peptides
18:00-18:25	Stefan Knapp, Goethe University Frankfurt, DE: Targeting epigenetic reader domains in cancer
18:30-18:55	Simone Fulda, Goethe University Frankfurt, DE: Novel opportunities for therapeutic targeting of cell death pathways
19:00	Conference Dinner (Foyer and Terrace First Floor)

Conference venue

Goethe University Frankfurt
Campus Westend / Casino, Room 823 (Festsaal)

Theodor-W.-Adorno-Platz 1
60323 Frankfurt am Main

Program takes place in Festsaal (Room 823) /
Casino building unless otherwise noted.

Contacts

Conference Managers

Dr. Stefanie Graf
stefanie.graf@kgu.de
Tel: +49 (0)69 / 6301-87763
Mobile: +49 (0)151 / 17191093

Birgit Rosiejak
rosiejak@em.uni-frankfurt.de
Tel: +49 (0)69 / 6301-5459

Supported by



Arthur und Margarete
Ebert-Stiftung



Frankfurt Cancer Conference

Turning molecular information
into novel cancer therapies

Program



Tuesday, 25 September 2018

16:00-18:00 Arrival & Registration (Foyer)
18:00-18:30 Welcome & Introduction: Christian Brandts,
University Cancer Center, Frankfurt, DE

18:30-19:30 Opening Session
Session Chairs: Ivan Dikic, Florian Greten

18:30-18:55 Tak W. Mak, University of Toronto, CA: Targeting genomic instability in cancer: dream or reality
19:00-19:25 René Bernards, Netherlands Cancer Institute, Amsterdam, NL: A one-two punch model for cancer therapy

19:30 Welcome Reception (Foyer)



www.frankfurtcancerconference.org

Wednesday, 26 September 2018

08:30-09:00	Registration (Foyer)
09:00-10:45	Session 1 – From cancer stem cells to tumor heterogeneity and treatment resistance Session Chairs: Daniela Krause, Richard Marais
09:00-09:25	Sean Morrison, University of Texas Southwestern, Dallas, US: The metabolic regulation of cancer progression
09:30-09:55	Priscilla K. Brastianos, Harvard Medical School, Boston, US: Genomic evolution of brain metastases
10:00-10:25	Andreas Trumpp, German Cancer Research Center, Heidelberg, DE: Stem cell features in cancer and therapy resistance
10:30-10:40	Anna Lorentzen, Aarhus University, Aarhus, DK: Liquid-phase single-cell polarity facilitates tumor cell attachment, adhesion and metastasis
10:45-11:15	Coffee Break (Foyer)
11:15-13:00	Session 2 – Novel approaches for improved precision oncology Session Chairs: René Bernards, Simone Fulda
11:15-11:40	Jürgen Ruland, Technical University Munich, DE: Antigen receptor and co-receptor signaling pathways in lymphoma: the dark side
11:45-11:55	Birgitta E. Michels, Georg-Speyer-Haus, Frankfurt, DE: Unbiased identification of tumor suppressor function by pooled CRISPR/Cas9 screening in human colon organoids
12:00-12:10	Kivanc Görgülü, Technical University Munich, DE: Levels of Autophagy-related gene (Atg5) determine pancreatic tumor formation and metastasis in mice
12:15-12:40	Lars Zender, University Hospital Tübingen, DE: Translating cancer biology: from functional target discovery to academic drug discovery and development
12:45-12:55	Simon Kreutzfeldt, National Center for Tumor Diseases, Heidelberg, DE: Integration of comprehensive molecular profiling into clinical practice

13:00-14:00	Lunch Break (Mensa)
14:00-16:15	Session 3 – From oncogenic signaling to targeting pathways Session Chairs: Laura Soucek, Peter Wild
14:00-14:10	Markus Morkel, Charité – Universitätsmedizin, Berlin, DE: Cell type-dependent differential activation of ERK by oncogenic KRAS or BRAF in the mouse intestinal epithelium
14:15-14:40	Stefan Pfister, National Center for Tumor Diseases Heidelberg, DE: Novel molecular targets in childhood brain tumors
14:45-15:10	Richard Marais, Cancer Research UK Manchester Institute, UK: Lysyl oxidase regulates tumor cellularity
15:15-15:40	Thomas Oellerich, Goethe University Frankfurt, DE: Therapeutic strategies revealed by proteogenomics
15:45-16:10	Bernhard Küster, Technical University Munich, DE: The target landscape of clinical kinase drugs
16:15-16:45	Coffee Break (Foyer)
16:45-18:30	Session 4 – Cancer metabolism: from understanding to intervention Session Chairs: Rolf Marschalek, Joachim Steinbach
16:45-17:10	Simone Niclou, Luxembourg Institute of Health, LU: Harnessing metabolic specificities of IDH mutant glioma for novel therapies
17:15-17:25	Dietrich A. Ruess, Technical University Munich, DE: Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
17:30-17:55	Matthew Vander Heiden, Massachusetts Institute of Technology, Cambridge, US: Considerations to target metabolism for cancer therapy
18:00-18:25	Karen Vousden, The Francis Crick Institute, London, UK: p53 pathways and cancer cell metabolism
18:30-20:00	Poster Session I & Finger Food (Foyer and Seminar Rooms First Floor)

Thursday, 27 September 2018

08:30-09:00	Registration (Foyer)
09:00-10:45	Session 5 – Tumor microenvironment and metastasis Session Chairs: Claus Rödel, Kimberly Stegmaier
09:00-09:25	Michael Karin, University of California San Diego, US: Metabolic and immune control of liver tumorigenesis
09:30-09:55	Florian Greten, Georg-Speyer-Haus, Frankfurt, DE: Modeling colorectal cancer progression
10:00-10:25	Raghu Kalluri, University of Texas, Houston, US: Functional contribution of tumor microenvironment and exosomes in the biology and treatment of pancreatic cancer
10:30-10:40	Ramona Schulz-Heddergott, University Medical Center Göttingen, DE: Therapeutic ablation of stabilized gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion
10:45-11:15	Coffee Break (Foyer)
11:15-12:45	Session 6 – Immunotherapy beyond checkpoint-inhibition Session Chairs: Bernhard Brüne, Tak W. Mak
11:15-11:40	Michael Platten, University Heidelberg, DE: Challenges in brain tumor immunotherapy
11:45-11:55	Fabian Coscia, University of Copenhagen, DK: Multi-level proteomics identifies a novel mediator of chemosensitivity and immunotherapy target in ovarian cancer
12:00-12:10	Emmanouil Fokas, Goethe University Frankfurt, DE: The stromal immune contexture of pancreatic ductal adenocarcinoma and rationale for combination of radiotherapy with immunotherapy
12:15-12:25	Frederic B. Thalheimer, Paul-Ehrlich-Institute, Langen, DE: In vivo generation of human CD19-CAR T cells results in B cell depletion and signs of cytokine release syndrome
12:30-12:55	Uğur Şahin, TRON - Translational Oncology at the University Medical Center Mainz, DE: Personalized cancer immunotherapy